Area of research
Hematology · Internal Medicine
Research interest
Research interests include Hemophilia Treatment and Research, Platelet Disorders and Treatments, Blood Coagulation and Thrombosis Mechanisms, and Venous Thromboembolism Diagnosis and Management.
Long-term doctor-patient communication: a patient‑reported perspective from a large Italian survey.
Medical devices in Europe, all but drugs: time to radically change their regulation?
Anticoagulant Therapy in Elderly Hospitalized Patients with Atrial Fibrillation: A Critical Appraisal of Data from the Italian REPOSI Registry.
Prescribing cascades among hospitalized older adults: a retrospective cohort study from the REPOSI registry.
Von Willebrand Disease Type 2A: An Update.
Environmental risk factors and cardiovascular health.
Hemophilia and hereditary angioedema: parallel therapeutic advances in genetic diseases of serine protease pathways
Anticoagulant Therapy in Elderly Hospitalized Patients with Atrial Fibrillation: A Critical Appraisal of Data from the Italian REPOSI Registry
Loneliness among older adults in Europe: time to integrate health and social care.
Association between long-term exposure to air pollution and incidence of peripheral artery disease: Evidence from a longitudinal study.
Bleeding Episodes in Patients With Haemophilia B Receiving Prophylactic Factor IX Treatment: A Systematic Review and Meta-Analysis.
Prescription of ACE-Is/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry.
Beyond the pills: tackling heart failure with a greener environment and more exercise.
Towards a sustainable pricing of pharmaceutical goods: comment.
On the Price of Valoctogene Roxaparvovec in Germany and Italy.
More on peripheral artery disease and air pollution. Author's reply.
von Willebrand disease combined with other hemostasis disorders: an overlooked clinical entity.
Low-dose emicizumab for more equitable access to prophylaxis in resource limited countries.
Rare inherited coagulation disorders: no longer orphan and neglected.
Environmental health and clinicians: time to promote more action.
UDCA treatment against COVID-19: Do we have enough clinical evidence for drug repurposing?
Pros and cons of the ISTH treatment guidelines for hemophilia.
Health and the environment: messages for the cardiologist.
Public regulation of private pharmacies in the European Union: time for a logical solution for retail distribution.
Acquired Hemophilia A after SARS-CoV-2 Immunization: A Narrative Review of a Rare Side Effect.
A European National Health and Social Service model: the S of social.
Drug prescription appropriateness in hospitalized older patients: 15-year results and lessons from a countrywide register.
Factor VIII and von Willebrand factor are wavering proteins: the basis for the therapeutic development of desmopressin.
Mortality during the SARS-CoV-2 Pandemic: A Comparative Analysis between Lombardy in Italy and Israel.
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.